Wire Stories
506Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR™
U.S. Clinical Trial Commencement Anticipated in 1Q2023 BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing...
- 574
ICPO Foundation and PreMIT Enter Strategic Partnership to Develop a Network of Precision Oncology and Theranostic Centers
First-of-its-kind global network will enable improved patient access to advanced precision cancer care, provide leading edge infrastructure using the most-advanced imaging technology,...
- 549
Momentus Signs Contract with Australian Research Centre to Place Satellite in Orbit
SAN JOSE, Calif.–(BUSINESS WIRE)–Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers transportation and other in-space...
- 488
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
— Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC — — Exscientia’s A2A biomarker signature for patient...
- 569
Momentus Signs Contract with Australian Research Centre to Place Satellite in Orbit
SAN JOSE, Calif.–(BUSINESS WIRE)–Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers transportation and other in-space...
- 616
Momentus Signs Contract with Australian Research Centre to Place Satellite in Orbit
SAN JOSE, Calif.–(BUSINESS WIRE)–Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers transportation and other in-space...
- 501
India Automotive Cybersecurity Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “India Automotive Cybersecurity Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s...
- 691
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
— Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC — — Exscientia’s A2A biomarker signature for patient...
- 629
HCLSoftware Launches a Brand-New Positioning of Fueling the Digital+ Economy
NOIDA, India & NEW YORK–(BUSINESS WIRE)–#AI—HCLSoftware, a division of HCL Technologies (HCLTech), launched its new brand identity and logo, positioning of Fueling...
- 691
HCLSoftware Launches a Brand-New Positioning of Fueling the Digital+ Economy
NOIDA, India & NEW YORK–(BUSINESS WIRE)–#AI—HCLSoftware, a division of HCL Technologies (HCLTech), launched its new brand identity and logo, positioning of Fueling...
